{"id":745504,"date":"2017-08-30T18:22:00","date_gmt":"2017-08-30T18:22:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/"},"modified":"2025-11-07T01:26:19","modified_gmt":"2025-11-07T06:26:19","slug":"new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/","title":{"rendered":"New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress"},"content":{"rendered":"<p class=\"bwalignc\">       Broad Set of Data for KEYTRUDA in 12 Types of Cancer as Monotherapy        and in Combination to be Presented     <\/p>\n<p class=\"bwalignc\">       Data Include Additional Results from KEYNOTE-021G in Non-Small Cell        Lung Cancer and First Presentation of Results from KEYNOTE-040 in        Advanced Head and Neck Squamous Cell Carcinoma     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that studies involving KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, in 12 different types<br \/>\n      of cancer will be presented at the European Society for Medical Oncology<br \/>\n      (ESMO) 2017 Congress in Madrid, Spain, Sept. 8-12. In total, 35<br \/>\n      abstracts \u2013 including data from studies investigating the use of<br \/>\n      KEYTRUDA as monotherapy and in novel combinations \u2013 were accepted for<br \/>\n      presentation at the congress, including five late-breaking<br \/>\n      abstracts.&nbsp;Data to be presented include studies of KEYTRUDA as<br \/>\n      monotherapy in advanced urothelial (bladder) carcinoma, gastric cancer,<br \/>\n      head and neck squamous cell carcinoma (HNSCC), microsatellite<br \/>\n      instability-high (MSI-H) or mismatch repair deficient cancer and<br \/>\n      triple-negative breast cancer (TNBC), as well as studies of KEYTRUDA in<br \/>\n      combination with other therapies in advanced non-small cell lung cancer<br \/>\n      (NSCLC), gastric cancer and melanoma.\n    <\/p>\n<p>\n      Merck\u2019s broad KEYTRUDA clinical development program includes more than<br \/>\n      30 tumor types in more than 550 clinical trials, including more than 300<br \/>\n      trials that combine KEYTRUDA with other cancer treatments.\n    <\/p>\n<p>\n      In addition to the data for KEYTRUDA to be presented at ESMO,<br \/>\n      researchers will also present data for LYNPARZA<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n      (olaparib), including the SOLO-2 and OlympiAD trials. For more<br \/>\n      information, including a complete list of KEYTRUDA (pembrolizumab) and<br \/>\n      LYNPARZA (olaparib) abstract titles, please see the ESMO program at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcslide.ctimeetingtech.com%2Flibrary%2Fesmo%2Fbrowse%2Fsearch%2FFag&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcslide.ctimeetingtech.com%2Flibrary%2Fesmo%2Fbrowse%2Fsearch%2FFag&amp;index=1&amp;md5=b9bc5f554a63813bfc18774939a60b6f\" rel=\"nofollow\">https:\/\/cslide.ctimeetingtech.com\/library\/esmo\/browse\/search\/Fag<\/a>.\n    <\/p>\n<p>\n      <span class=\"bwuline\">Late-Breaking KEYTRUDA Abstracts<\/span><br \/>\n<br \/>In<br \/>\n      total, five KEYTRUDA abstracts were selected as late-breaking abstracts.<br \/>\n      In lung cancer, an additional five-months of follow-up from the phase 2<br \/>\n      KEYNOTE-021 trial, Cohort G, which is studying KEYTRUDA in combination<br \/>\n      with pemetrexed\/carboplatin for the first-line treatment of NSCLC, will<br \/>\n      be presented. Three abstracts will be featured in the official ESMO<br \/>\n      press program, including results for KEYTRUDA in advanced gastric<br \/>\n      cancer, as monotherapy and in combination therapy, from the multi-cohort<br \/>\n      phase 2 KEYNOTE-059 trial; longer-term overall survival data for<br \/>\n      KEYTRUDA versus chemotherapy for urothelial carcinoma from the phase 3<br \/>\n      KEYNOTE-045 trial; and, the first-time presentation of data for KEYTRUDA<br \/>\n      monotherapy in previously treated patients with recurrent or metastatic<br \/>\n      HNSCC from the phase 3 KEYNOTE-040 trial.\n    <\/p>\n<p>\n      Further information on late-breaking abstracts for KEYTRUDA:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>NSCLC:<\/b> (Abstract #LBA49) Proffered Paper Session: Updated<br \/>\n        results from KEYNOTE-021 cohort G: a randomized, phase 2 study of<br \/>\n        pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro)<br \/>\n        as first-line therapy for advanced nonsquamous NSCLC. H. Borghaei.<br \/>\n        Friday, Sept. 8, 5:03 \u2013 5:15 p.m. CEST. Location: Madrid Auditorium.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Gastric Cancer:<\/b> (Abstract #LBA28_PR) Proffered Paper Session:<br \/>\n        KEYNOTE-059 update: efficacy and safety of pembrolizumab alone or in<br \/>\n        combination with chemotherapy in patients with advanced gastric or<br \/>\n        gastroesophageal (G\/GEJ) cancer. Z. A. Wainberg. Friday, Sept. 8, 3:03<br \/>\n        \u2013 3:15 p.m. CEST. Location: Barcelona Auditorium.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Urothelial Carcinoma:<\/b> (Abstract #LBA37_PR) Poster Discussion<br \/>\n        Session: Pembrolizumab (pembro) versus paclitaxel, docetaxel, or<br \/>\n        vinflunine for recurrent, advanced urothelial cancer (UC): mature<br \/>\n        results from the phase 3 KEYNOTE-045 trial. R. De Wit. Sunday, Sept.<br \/>\n        10 Poster: 2:45 \u2013 4:15 p.m. CEST. Discussion: 3:15 \u2013 3:45 p.m. CEST.<br \/>\n        Location: Cordoba Auditorium.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>HNSCC:<\/b> (Abstract #LBA45_PR) Proffered Paper Session:<br \/>\n        Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or<br \/>\n        metastatic head and neck squamous cell carcinoma (R\/M HNSCC): Phase 3<br \/>\n        KEYNOTE-040 trial. E. E. Cohen. Monday, Sept. 11, 3:00 \u2013 3:12 p.m.<br \/>\n        CEST. Location: Granada Auditorium.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Breast Cancer:<\/b> (Abstract #LBA13) Proffered Paper Session:<br \/>\n        Relationship between tumor infiltrating lymphocyte (TIL) levels and<br \/>\n        response to pembrolizumab (pembro) in metastatic triple-negative<br \/>\n        breast cancer (mTNBC): results from KEYNOTE-086. S. Loi. Saturday,<br \/>\n        Sept. 9, 11:45 \u2013 12:00 p.m. CEST. Location: Madrid Auditorium.\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\">Additional KEYTRUDA (pembrolizumab) Abstracts<\/span><br \/>\n<br \/>Combination<br \/>\n      data at ESMO include findings from the phase 1\/2 ECHO-202\/KEYNOTE-037<br \/>\n      trial of KEYTRUDA in combination with epacadostat, Incyte\u2019s<br \/>\n      investigational oral selective IDO1 enzyme inhibitor, in advanced<br \/>\n      melanoma, as well as findings from the phase 1b\/2 trial of KEYTRUDA with<br \/>\n      Eisai\u2019s multiple receptor tyrosine kinase inhibitor, Lenvima<sup>\u00ae<\/sup><br \/>\n      (lenvatinib), in advanced renal cell carcinoma. Monotherapy data include<br \/>\n      findings from the phase 1 KEYNOTE-028 trial studying KEYTRUDA in PD-L1<br \/>\n      positive advanced carcinoid or pancreatic cancer and findings from the<br \/>\n      KEYNOTE-164 and KEYNOTE-158 studies of KEYTRUDA in MSI-H cancers.\n    <\/p>\n<p>\n      Further information on select KEYTRUDA abstracts:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>Renal Cell Cancer:<\/b> (Abstract #847O) Proffered Paper Session: A<br \/>\n        Phase 1b\/2 trial of lenvatinib plus pembrolizumab in patients with<br \/>\n        renal cell carcinoma. C. Lee. Saturday, Sept. 9, 10:15 \u2013 10:30 a.m.<br \/>\n        CEST. Location: Madrid Auditorium.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Melanoma:<\/b> (Abstract #1214O) Proffered Paper Session:<br \/>\n        Epacadostat plus pembrolizumab in patients with advanced melanoma:<br \/>\n        phase 1 and 2 efficacy and safety results from ECHO-202\/KEYNOTE-037.<br \/>\n        O. Hamid. Saturday, Sept. 9, 3:00 \u2013 3:15 p.m. CEST. Location: Madrid<br \/>\n        Auditorium.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Melanoma:<\/b> (Abstract #1216O) Proffered Paper Session:<br \/>\n        KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro)<br \/>\n        plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced<br \/>\n        melanoma. A. Ribas. Saturday, Sept. 9, 3:45 \u2013 4:00 p.m. CEST.<br \/>\n        Location: Madrid Auditorium.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Pancreatic Cancer:<\/b> (Abstract #427O) Proffered Paper Session:<br \/>\n        Pembrolizumab for patients with PD-L1\u2013positive advanced carcinoid or<br \/>\n        pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study.<br \/>\n        J. M. Mehnert. Sunday, Sept. 10, 4:30 \u2013 4:42 p.m. CEST. Location:<br \/>\n        Tarragona Auditorium.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Advanced MSI-H Cancer:<\/b> (Abstract #386P) Poster Display Session:<br \/>\n        Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158<br \/>\n        studies of microsatellite instability high cancers. L. Diaz. Monday,<br \/>\n        Sept. 11, 1:15 \u2013 2:15 p.m. CEST. Location: Hall 8.\n      <\/li>\n<\/ul>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b><br \/>\n<br \/>On<br \/>\n      July 27, 2017, AstraZeneca and Merck &amp; Co., Inc. announced a global<br \/>\n      strategic oncology collaboration to co-develop and co-commercialize<br \/>\n      AstraZeneca\u2019s LYNPARZA, the world\u2019s first PARP inhibitor, and potential<br \/>\n      new medicine selumetinib, a MEK inhibitor, for multiple cancer types.<br \/>\n      The collaboration is based on increasing evidence that PARP and MEK<br \/>\n      inhibitors can be combined with PDL-1\/PD-1 inhibitors for a range of<br \/>\n      tumor types. Working together, the companies will jointly develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as a monotherapy. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<br \/>\n      100mg<\/b><br \/>\n<br \/>KEYTRUDA is an anti-PD-1 therapy that works by increasing<br \/>\n      the ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA is a humanized monoclonal antibody that blocks the<br \/>\n      interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby<br \/>\n      activating T lymphocytes which may affect both tumor cells and healthy<br \/>\n      cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 550 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the treatment of patients<br \/>\n      with unresectable or metastatic melanoma at a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i><br \/>\n<br \/>KEYTRUDA, as a single agent, is indicated for<br \/>\n      the first-line treatment of patients with metastatic non-small cell lung<br \/>\n      cancer (NSCLC) whose tumors have high PD-L1 expression [tumor proportion<br \/>\n      score (TPS) \u226550%] as determined by an FDA-approved test, with no EGFR or<br \/>\n      ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab), as a single agent, is also indicated for the<br \/>\n      treatment of patients with metastatic NSCLC whose tumors express PD-L1<br \/>\n      (TPS \u22651%) as determined by an FDA-approved test, with disease<br \/>\n      progression on or after platinum-containing chemotherapy. Patients with<br \/>\n      EGFR or ALK genomic tumor aberrations should have disease progression on<br \/>\n      FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the treatment<br \/>\n      of patients with recurrent or metastatic head and neck squamous cell<br \/>\n      carcinoma (HNSCC) with disease progression on or after<br \/>\n      platinum-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. In HNSCC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the<br \/>\n      treatment of adult and pediatric patients with refractory classical<br \/>\n      Hodgkin lymphoma (cHL), or who have relapsed after three or more prior<br \/>\n      lines of therapy. This indication is approved under accelerated approval<br \/>\n      based on tumor response rate and durability of response. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials. In adults<br \/>\n      with cHL, KEYTRUDA is administered at a fixed dose of 200 mg every three<br \/>\n      weeks until disease progression or unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression. In pediatric patients<br \/>\n      with cHL, KEYTRUDA (pembrolizumab) is administered at a dose of 2 mg\/kg<br \/>\n      (up to a maximum of 200 mg) every three weeks until disease progression<br \/>\n      or unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the treatment<br \/>\n      of patients with locally advanced or metastatic urothelial carcinoma who<br \/>\n      are not eligible for cisplatin-containing chemotherapy. This indication<br \/>\n      is approved under accelerated approval based on tumor response rate and<br \/>\n      duration of response. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i><br \/>\n<br \/>KEYTRUDA is<br \/>\n      indicated for the treatment of adult and pediatric patients with<br \/>\n      unresectable or metastatic microsatellite instability-high (MSI-H) or<br \/>\n      mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b><br \/>\n<br \/>KEYTRUDA<br \/>\n      can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC, occurring in 28 (15%) of 192 patients<br \/>\n      with HNSCC, including Grade 3 (5%) hypothyroidism. Thyroiditis occurred<br \/>\n      in 16 (0.6%) of 2799 patients receiving KEYTRUDA (pembrolizumab),<br \/>\n      including Grade 2 (0.3%) thyroiditis. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs and symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA (pembrolizumab). Treatment with KEYTRUDA may increase the<br \/>\n      risk of rejection in solid organ transplant recipients. Consider the<br \/>\n      benefit of treatment with KEYTRUDA vs the risk of possible organ<br \/>\n      rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA (pembrolizumab) occurred in 21% of patients; the most common<br \/>\n      (\u22651%) was diarrhea (2.5%). The most common adverse reactions with<br \/>\n      KEYTRUDA vs ipilimumab were fatigue (28% vs 28%), diarrhea (26% with<br \/>\n      KEYTRUDA), rash (24% vs 23%), and nausea (21% with KEYTRUDA).<br \/>\n      Corresponding incidence rates are listed for ipilimumab only for those<br \/>\n      adverse reactions that occurred at the same or lower rate than with<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682 patients with metastatic NSCLC. The most common adverse event<br \/>\n      resulting in permanent discontinuation of KEYTRUDA was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      When KEYTRUDA was administered in combination with carboplatin and<br \/>\n      pemetrexed (carbo\/pem), KEYTRUDA was discontinued in 10% of 59 patients.<br \/>\n      The most common adverse reaction resulting in discontinuation of<br \/>\n      KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 39% of patients; the most common<br \/>\n      (\u22652%) were fatigue (8%), neutrophil count decreased (8%), anemia (5%),<br \/>\n      dyspnea (3.4%), and pneumonitis (3.4%). The most common adverse<br \/>\n      reactions (\u226520%) with KEYTRUDA compared to carbo\/pem alone were fatigue<br \/>\n      (71% vs 50%), nausea (68% vs 56%), constipation (51% vs 37%), rash (42%<br \/>\n      vs 21%), vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs<br \/>\n      23%), decreased appetite (31% vs 23%), headache (31% vs 16%), cough (24%<br \/>\n      vs 18%), dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs<br \/>\n      4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia<br \/>\n      (20% vs 3.2%), upper respiratory tract infection (20% vs 3.2%), and<br \/>\n      arthralgia (15% vs 24%). This study was not designed to demonstrate a<br \/>\n      statistically significant difference in adverse reaction rates for<br \/>\n      KEYTRUDA as compared to carbo\/pem alone for any specified adverse<br \/>\n      reaction.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL, and treatment was interrupted due to adverse<br \/>\n      reactions in 26% of patients. Fifteen percent (15%) of patients had an<br \/>\n      adverse reaction requiring systemic corticosteroid therapy. Serious<br \/>\n      adverse reactions occurred in 16% of patients. The most frequent serious<br \/>\n      adverse reactions (\u22651%) included pneumonia, pneumonitis, pyrexia,<br \/>\n      dyspnea, GVHD, and herpes zoster. Two patients died from causes other<br \/>\n      than disease progression; one from GVHD after subsequent allogeneic HSCT<br \/>\n      and one from septic shock. The most common adverse reactions (occurring<br \/>\n      in \u226520% of patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (20%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated<br \/>\n      patients, the most frequent (\u22652%) of which were urinary tract infection,<br \/>\n      pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u2265 20% patients) were<br \/>\n      fatigue, pruritus, diarrhea, decreased appetite, rash, pyrexia, cough,<br \/>\n      dyspnea, musculoskeletal pain, constipation and nausea.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b><br \/>\n<br \/>LYNPARZA<br \/>\n      was the first FDA-approved oral poly ADP-ribose polymerase (PARP)<br \/>\n      inhibitor that may exploit tumor DNA damage response (DDR) pathway<br \/>\n      deficiencies to potentially kill cancer cells. Specifically, <i>in vitro<\/i><br \/>\n      studies have shown that olaparib-induced cytotoxicity may involve<br \/>\n      inhibition of PARP enzymatic activity and increased formation of<br \/>\n      PARP-DNA complexes, resulting in DNA damage and cancer cell death.\n    <\/p>\n<p>\n      LYNPARZA (olaparib) tablets are currently being investigated in<br \/>\n      combinations in a range of tumor types, including breast, prostate, and<br \/>\n      pancreatic cancer.\n    <\/p>\n<p>\n      LYNPARZA capsules (400mg twice daily) will still be available through a<br \/>\n      limited specialty pharmacy network, for patients currently being treated<br \/>\n      for deleterious or suspected deleterious germline BRCA-mutated advanced<br \/>\n      ovarian cancer who have been treated with three or more prior lines of<br \/>\n      chemotherapy. LYNPARZA tablets and capsules are not the same.\n    <\/p>\n<p>\n      If you have been prescribed LYNPARZA tablets, do not take the capsules.<br \/>\n      If you have any questions about LYNPARZA, please talk with your<br \/>\n      physician or pharmacist.\n    <\/p>\n<p>\n      <b>LYNPARZA Important Safety Information<\/b>\n    <\/p>\n<p>\n      <b>Dosing and Administration<\/b><br \/>\n<br \/>To avoid substitution errors and<br \/>\n      overdose, <b>do not substitute LYNPARZA tablets with LYNPARZA capsules <\/b>on<br \/>\n      a milligram-to-milligram basis due to differences in the dosing and<br \/>\n      bioavailability of each formulation. Recommended tablet dose is 300 mg,<br \/>\n      taken orally twice daily, with or without food. Continue treatment until<br \/>\n      disease progression or unacceptable toxicity. For adverse reactions,<br \/>\n      consider dose interruption or dose reduction.\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b><br \/>\n<br \/>There are no contraindications for<br \/>\n      LYNPARZA.\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML):&nbsp;<\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some of these<br \/>\n      patients also had a history of previous cancer or bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA (olaparib) until patients have recovered from<br \/>\n      hematological toxicity caused by previous chemotherapy (\u2264Grade 1).<br \/>\n      Monitor complete blood counts for cytopenia at baseline and monthly<br \/>\n      thereafter for clinically significant changes during treatment. For<br \/>\n      prolonged hematological toxicities, interrupt LYNPARZA and monitor blood<br \/>\n      counts weekly until recovery. If the levels have not recovered to Grade<br \/>\n      1 or less after 4 weeks, refer the patient to a hematologist for further<br \/>\n      investigations, including bone marrow analysis and blood sample for<br \/>\n      cytogenetics. Discontinue LYNPARZA if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis:<\/b>&nbsp;Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt treatment with LYNPARZA and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity:<\/b>&nbsp;Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment. Advise females of reproductive potential of the potential<br \/>\n      risk to a fetus and to use effective contraception during treatment and<br \/>\n      for 6 months after receiving the final dose.\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Maintenance Setting<\/b><br \/>\n<br \/>Most common adverse<br \/>\n      reactions (Grades 1-4) in \u226520% of patients in clinical trials of<br \/>\n      LYNPARZA in the <b>maintenance setting&nbsp;<\/b>for&nbsp;<b>SOLO-2<\/b>:&nbsp;nausea<br \/>\n      (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%),<br \/>\n      nasopharyngitis\/upper respiratory tract infection (URI)\/influenza (36%),<br \/>\n      diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%), headache<br \/>\n      (26%), decreased appetite (22%), and stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19:<\/b> nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the&nbsp;<b>maintenance setting<br \/>\n      (SOLO-2\/Study 19<\/b>) were: increase in mean corpuscular volume<br \/>\n      (89%\/82%), decrease in hemoglobin (83%\/82%), decrease in leukocytes<br \/>\n      (69%\/58%), decrease in lymphocytes (67%\/52%), decrease in absolute<br \/>\n      neutrophil count (51%\/47%), increase in serum creatinine (44%\/45%), and<br \/>\n      decrease in platelets (42%\/36%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Advanced g<i>BRCA<\/i>m ovarian cancer<\/b><br \/>\n<br \/>Most<br \/>\n      common adverse reactions (Grades 1-4) in \u226520% of patients in clinical<br \/>\n      trials of LYNPARZA (olaparib) for <b>advanced g<i>BRCA<\/i>m ovarian<br \/>\n      cancer after 3 or more lines of chemotherapy<\/b> (pooled from 6 studies)<br \/>\n      were: fatigue (including asthenia) (66%), nausea (64%), vomiting (43%),<br \/>\n      anemia (34%), diarrhea (31%), nasopharyngitis\/upper respiratory tract<br \/>\n      infection (URI) (26%), dyspepsia (25%), myalgia (22%), decreased<br \/>\n      appetite (22%), and arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy<\/b> (pooled from 6 studies) were:<br \/>\n      decrease in hemoglobin (90%), increase in mean corpuscular volume (57%),<br \/>\n      decrease in lymphocytes (56%), increase in serum creatinine (30%),<br \/>\n      decrease in platelets (30%), and decrease in absolute neutrophil count<br \/>\n      (25%).\n    <\/p>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents:<\/b>&nbsp;Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors:<\/b>&nbsp;Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must<br \/>\n      be&nbsp;co-administered, reduce the dose of LYNPARZA. Advise patients to<br \/>\n      avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange<br \/>\n      juice during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers:<\/b>&nbsp;Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      be aware of a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>Use in Specific Populations<\/b>\n    <\/p>\n<p>\n      <b>Pediatric Use:<\/b> The safety and efficacy of LYNPARZA (olaparib)<br \/>\n      have not been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Lactation:<\/b>&nbsp;No data are available regarding the presence of<br \/>\n      olaparib in human milk, the effects on the breastfed infant, or the<br \/>\n      effects on milk production. Because of the potential for serious adverse<br \/>\n      reactions in the breastfed infant, advise a lactating woman not to<br \/>\n      breastfeed during treatment with LYNPARZA and for 1 month after<br \/>\n      receiving the final dose.\n    <\/p>\n<p>\n      <b>Hepatic Impairment:<\/b>&nbsp;No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment:<\/b>&nbsp;No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment&nbsp;(CLcr 51-80 mL\/min).&nbsp;In patients<br \/>\n      with moderate renal impairment&nbsp;(CLcr 31-50 mL\/min),&nbsp;reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or&nbsp;end-stage&nbsp;renal disease&nbsp;(CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>APPROVED USES for LYNPARZA<\/b><br \/>\n<br \/>LYNPARZA is a poly (ADP-ribose)<br \/>\n      polymerase (PARP) inhibitor indicated:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        For the maintenance treatment of adult patients with recurrent<br \/>\n        epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n        are in complete or partial response to&nbsp;platinum-based&nbsp;chemotherapy\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        For the treatment of adult patients with deleterious or suspected<br \/>\n        deleterious germline&nbsp;BRCA-mutated advanced ovarian cancer who have<br \/>\n        been treated with 3 or more prior lines of chemotherapy. Select<br \/>\n        patients for therapy based on an FDA-approved companion diagnostic for<br \/>\n        LYNPARZA\n      <\/li>\n<\/ul>\n<p>\n      <b>Our Focus on Cancer<\/b><br \/>\n<br \/>Our goal is to translate breakthrough<br \/>\n      science into innovative oncology medicines to help people with cancer<br \/>\n      worldwide. At Merck, helping people fight cancer is our passion and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. Our<br \/>\n      focus is on pursuing research in immuno-oncology and we are accelerating<br \/>\n      every step in the journey \u2013 from lab to clinic \u2013 to potentially bring<br \/>\n      new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 550 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=e227f5b3284e25db022f4f946ca6e768\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b><br \/>\n<br \/>For more than a century, Merck, a leading global<br \/>\n      biopharmaceutical company known as MSD outside of the United States and<br \/>\n      Canada, has been inventing for life, bringing forward medicines and<br \/>\n      vaccines for many of the world\u2019s most challenging diseases. Through our<br \/>\n      prescription medicines, vaccines, biologic therapies and animal health<br \/>\n      products, we work with customers and operate in more than 140 countries<br \/>\n      to deliver innovative health solutions. We also demonstrate our<br \/>\n      commitment to increasing access to health care through far-reaching<br \/>\n      policies, programs and partnerships. Today, Merck continues to be at the<br \/>\n      forefront of research to advance the prevention and treatment of<br \/>\n      diseases that threaten people and communities around the world &#8211;<br \/>\n      including cancer, cardio-metabolic diseases, emerging animal diseases,<br \/>\n      Alzheimer\u2019s disease and infectious diseases including HIV and Ebola. For<br \/>\n      more information, visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=8c367d923674f9f2160b7078d02ae132\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=89b56f1f248f88cebe985a02e1fcb93a\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=6818cea893839c2e42f9a0d8a15698c5\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=d02c5ebca8ac905b9b23a93d6e0fb44d\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=7dcb0efe67d8725c6fafe697065887c4\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=744bb486100c6e9234a5f55ffdc55c4e\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b><br \/>\n<br \/>This<br \/>\n      news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d)<br \/>\n      includes \u201cforward-looking statements\u201d within the meaning of the safe<br \/>\n      harbor provisions of the U.S. Private Securities Litigation Reform Act<br \/>\n      of 1995. These statements are based upon the current beliefs and<br \/>\n      expectations of the company\u2019s management and are subject to significant<br \/>\n      risks and uncertainties. There can be no guarantees with respect to<br \/>\n      pipeline products that the products will receive the necessary<br \/>\n      regulatory approvals or that they will prove to be commercially<br \/>\n      successful. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=375ebcb468869871efa1394e36aaa367\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=10&amp;md5=a951e308e87a7340c11a8d0ca23906eb\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=11&amp;md5=a2f9923cd2f1d2ca9dbfd36e7bc8a539\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>Please see complete <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.azpicentral.com%2Flynparza_tb%2Fpi_lynparza_tb.pdf%23page%3D1&amp;esheet=51676513&amp;newsitemid=20170830006315&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=12&amp;md5=62cb1c38b8e9cba1373c37579af1b43b\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b> for LYNPARZA (olaparib), including Patient<br \/>\n      Information (Medication Guide).<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170830006315r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Kim        Hamilton, 908-740-1863<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Broad Set of Data for KEYTRUDA in 12 Types of Cancer as Monotherapy and in Combination to be Presented Data Include Additional Results from KEYNOTE-021G in Non-Small Cell Lung Cancer and First Presentation of Results from KEYNOTE-040 in Advanced Head and Neck Squamous Cell Carcinoma Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that studies involving KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in 12 different types of cancer will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, Sept. 8-12. In total, 35 abstracts \u2013 including data from studies investigating the use of KEYTRUDA as monotherapy and in novel combinations \u2013 were accepted for presentation at the congress, including five late-breaking abstracts.&nbsp;Data to be presented include studies of KEYTRUDA as monotherapy in advanced urothelial (bladder) carcinoma, gastric cancer, head and neck squamous cell carcinoma (HNSCC),<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745504","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Broad Set of Data for KEYTRUDA in 12 Types of Cancer as Monotherapy and in Combination to be Presented Data Include Additional Results from KEYNOTE-021G in Non-Small Cell Lung Cancer and First Presentation of Results from KEYNOTE-040 in Advanced Head and Neck Squamous Cell Carcinoma Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that studies involving KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in 12 different types of cancer will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, Sept. 8-12. In total, 35 abstracts \u2013 including data from studies investigating the use of KEYTRUDA as monotherapy and in novel combinations \u2013 were accepted for presentation at the congress, including five late-breaking abstracts.&nbsp;Data to be presented include studies of KEYTRUDA as monotherapy in advanced urothelial (bladder) carcinoma, gastric cancer, head and neck squamous cell carcinoma (HNSCC),\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"26 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\\\/\",\"name\":\"New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-08-30T18:22:00+00:00\",\"dateModified\":\"2025-11-07T06:26:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/","og_locale":"en_US","og_type":"article","og_title":"New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress - Merck.com","og_description":"Broad Set of Data for KEYTRUDA in 12 Types of Cancer as Monotherapy and in Combination to be Presented Data Include Additional Results from KEYNOTE-021G in Non-Small Cell Lung Cancer and First Presentation of Results from KEYNOTE-040 in Advanced Head and Neck Squamous Cell Carcinoma Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that studies involving KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in 12 different types of cancer will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, Sept. 8-12. In total, 35 abstracts \u2013 including data from studies investigating the use of KEYTRUDA as monotherapy and in novel combinations \u2013 were accepted for presentation at the congress, including five late-breaking abstracts.&nbsp;Data to be presented include studies of KEYTRUDA as monotherapy in advanced urothelial (bladder) carcinoma, gastric cancer, head and neck squamous cell carcinoma (HNSCC),","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:19+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"26 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/","name":"New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-08-30T18:22:00+00:00","dateModified":"2025-11-07T06:26:19+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-and-updated-data-for-keytruda-pembrolizumab-from-mercks-extensive-immuno-oncology-program-to-be-presented-at-the-esmo-2017-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New and Updated Data for KEYTRUDA\u00ae (pembrolizumab) from Merck\u2019s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"348524b2-0243-4b55-b80f-d0daf594becf","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-and-Updated-Data-for-KEYTRUDA-pembrolizumab-from-Mercks-Extensive-Immuno-Oncology-Program-to-be-Presented-at-the-ESMO-2017-Congress-2017.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745504\/revisions"}],"predecessor-version":[{"id":3674860,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745504\/revisions\/3674860"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745504"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}